Watch DMAC. Know when insiders buy.
One email the day a filing lands. Free.
DMAC
DiaMedica Therapeutics Inc.
6.47
−0.12 −1.82%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $348.9MP/E —DIV YIELD —FCF YIELD -9.04%REV TTM —NET INCOME −$37.5MNET CASH —52W 5.33 – 9.39SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.5M | −$10.1M | — | -0.19 | −$8.1M | $3K | −$8.1M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$10.5M | −$10M | — | -0.19 | −$9.1M | $8K | −$9.1M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.2M | −$8.7M | — | -0.17 | −$7.8M | $6K | −$7.8M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$9M | −$8.6M | — | -0.17 | −$6.5M | $16K | −$6.6M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$8M | −$7.7M | — | -0.18 | −$7.6M | $6K | −$7.6M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$8.1M | −$7.7M | — | -0.18 | −$7.1M | $12K | −$7.2M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.4M | −$7.9M | — | -0.18 | −$6.4M | $7K | −$6.4M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$6.9M | −$6.3M | — | -0.15 | −$4.5M | $9K | −$4.5M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$5.6M | −$5.1M | — | -0.13 | −$4.5M | $0 | −$4.5M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$5.7M | −$5.2M | — | -0.14 | −$6.7M | $9K | −$6.7M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.8M | −$5.2M | — | -0.14 | −$3.8M | $3K | −$3.8M | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | −$5.2M | −$4.5M | — | -0.12 | −$4.8M | $10K | −$4.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$34.4M | −$32.8M | — | -0.70 | −$29.1M | $40K | −$29.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$26.7M | −$24.4M | — | -0.60 | −$22.1M | $25K | −$22.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$21.3M | −$19.4M | — | -0.60 | −$18.7M | $24K | −$18.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$14M | −$13.7M | — | -0.52 | −$11.5M | $81K | −$11.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$13.6M | −$13.6M | — | -0.65 | −$12.3M | $22K | −$12.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$12.7M | −$12.3M | — | -0.78 | −$9.2M | $47K | −$9.2M | — | — |
Every number comes from DiaMedica Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.